Q1 Earnings Forecast for BBIO Issued By Leerink Partnrs

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for BridgeBio Pharma in a note issued to investors on Monday, February 24th. Leerink Partnrs analyst M. Foroohar anticipates that the company will post earnings of ($0.73) per share for the quarter. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s Q2 2025 earnings at ($0.85) EPS, FY2025 earnings at ($3.40) EPS, FY2026 earnings at ($1.79) EPS, FY2027 earnings at $0.40 EPS, FY2028 earnings at $3.10 EPS and FY2029 earnings at $4.85 EPS.

A number of other research firms also recently commented on BBIO. Citigroup lifted their target price on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Bank of America lifted their price objective on BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, November 25th. Cantor Fitzgerald reissued an “overweight” rating and issued a $95.00 target price on shares of BridgeBio Pharma in a report on Friday, February 21st. Scotiabank boosted their price target on BridgeBio Pharma from $49.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Friday, February 21st. Finally, Evercore ISI upped their price target on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $51.67.

BridgeBio Pharma Stock Up 2.6 %

Shares of BBIO stock opened at $34.30 on Wednesday. The company has a 50 day moving average price of $32.51 and a 200-day moving average price of $28.21. BridgeBio Pharma has a 52 week low of $21.62 and a 52 week high of $39.47. The firm has a market capitalization of $6.52 billion, a PE ratio of -12.04 and a beta of 1.07.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million during the quarter, compared to analyst estimates of $4.04 million.

Insider Buying and Selling

In related news, CEO Neil Kumar sold 326,932 shares of the firm’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total transaction of $11,864,362.28. Following the completion of the transaction, the chief executive officer now directly owns 5,371,515 shares of the company’s stock, valued at approximately $194,932,279.35. This trade represents a 5.74 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Brian C. Stephenson sold 8,500 shares of the business’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $33.19, for a total transaction of $282,115.00. Following the completion of the sale, the chief financial officer now owns 102,464 shares in the company, valued at approximately $3,400,780.16. The trade was a 7.66 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,579,739 shares of company stock valued at $125,411,901. Company insiders own 24.66% of the company’s stock.

Institutional Investors Weigh In On BridgeBio Pharma

Several large investors have recently made changes to their positions in BBIO. Creative Planning purchased a new position in BridgeBio Pharma during the 3rd quarter valued at approximately $772,000. Allspring Global Investments Holdings LLC grew its holdings in shares of BridgeBio Pharma by 17.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company’s stock valued at $135,000 after purchasing an additional 801 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in BridgeBio Pharma by 21.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,801 shares of the company’s stock worth $170,000 after purchasing an additional 1,214 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in BridgeBio Pharma by 64.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 36,165 shares of the company’s stock worth $921,000 after purchasing an additional 14,181 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust raised its stake in BridgeBio Pharma by 50.8% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 751,355 shares of the company’s stock valued at $19,129,000 after purchasing an additional 253,101 shares in the last quarter. 99.85% of the stock is owned by institutional investors.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.